Enveric Biosciences (ENVB) Long-Term Investments (2015 - 2016)
Enveric Biosciences (ENVB) posted Long-Term Investments of $82908.0 for Q4 2016, little changed sequentially from $82908.0 in Q4 2015, and little changed YoY from $82908.0 in Q1 2016.
Enveric Biosciences (ENVB) Long-Term Investments (2015 - 2016) Analysis & Trends
Enveric Biosciences has reported Long-Term Investments for 2 years, with the latest figure at $82908.0 in Q4 2016.
- Quarterly Long-Term Investments changed 0.0% year-over-year to $82908.0 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $82908.0 (changed 0.0% YoY) and the FY2016 annual result came in at $82908.0, changed 0.0% from the prior year.
- Long-Term Investments was little changed at $82908.0 in Q4 2016 per ENVB's latest filing, from $82908.0 in the prior quarter.
- Over five years, Long-Term Investments peaked at $340000.0 in Q1 2015 and troughed at $82908.0 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 82,908.00 |
| Dec 31, 2015 | 82,908.00 |
| Mar 31, 2015 | 340,000.00 |